Discovery and Characterization of a Novel Bacteriocin That Strongly Inhibits Staphylococcus aureus

Abstract

Drug resistance in Staphylococcus aureus is a serious problem, and the development of new antimicrobial drugs to circumvent drug resistance has become a trend. In this study, we isolated a strain of Bacillus subtilis with high tolerance to alcohol, pH, NaCl, bile salt, surfactants, temperature, and simulated intestinal fluids. We optimized culture parameters to obtain the best fermentation conditions for the production of inhibitory compounds in cell-free culture media. The crude extract showed excellent stability when exposed to temperature, pH, and ultraviolet radiation, with almost no loss of bacteriostatic activity after treatment. After isolation and purification, the peptide sequences were identified using ultraperformance liquid chromatography–mass spectrometry (UPLC–MS), and the antibacterial sequences were analyzed using bioinformatics. The results of the identification showed that there was one novel bacteriocin (NSGGSYGSGGGGGGGNSHGY) with a molecular weight of 1513.58 Da. The minimum inhibitory concentration (MIC) of the B5 bacteriocin was 31.25 μg/mL against S. aureus, and it is noteworthy that bacteriocin B5 also showed weak antibacterial activity against Vibrio parahaemolyticus. In conclusion, this study developed a novel bacteriocin that has the potential to be used as an alternative to S. aureus antibiotics.